About UNAIDS News and Events The UN in China Information Centre
Document title search:
Link to Full List | Please email china@unaids.org to request hard copies.
pdf | | Download
New report aims to inspire more investment from China into Africa’s pharmaceutical sector

4 December 2018-- A new report launched today jointly by UNAIDS and the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) highlights the vast opportunities for Chinese pharmaceutical companies to relocate their manufacturing to African countries, not only to provide cheaper, high-quality drugs but also jobs, technology and skills transfer.

 

Currently, Africa imports 70% of its pharmaceutical products and only 34 of 55 African countries have some level of pharmaceutical production. With around 47% of people in Africa still not receiving vital access to good quality medicines, alongside increasing trade deficits and a growing demand for local jobs, the high level of imports is vastly unsustainable for the continent.

 

Health has been a long-standing part of commitments from China to African countries. However, in 2017, China made up only 5% of the total pharmaceutical imports to Africa as a whole, and only a handful of Chinese companies are actuallymanufacturing on the continent.

 

Against this background, the report released today by UNAIDS and CCCMHPIE, and produced by Development Reimagined a consulting firm based in Beijing, provides a comprehensive overview of 21 African countries as a consistent, attractive set of “profiles” to help ambitious Chinese pharmaceutical players take their first steps in understanding the opportunities and landscape in the emerging continent.

 

Explaining the vision for the report, Amakobe Sande, UNAIDS Country Director and Representative in China said: “The needs on the continent are very high, including for HIV/AIDS medicines. Yet China is not yet making a mark. This is not about favouring Chinese companies, but it is about sharing the health market investment opportunity with them in a way that they might also create much needed jobs”.

 

Key findings from the report show that in 18 of the 21 countries, pharmaceutical production is considered a national priority, highlighting the demand for and commitment to local production amongst the surveyed countries. The report also shows that all the 21 countries already import Chinese health products, including limited TCM products, which occupy a maximum of 5% market share amongst the 21 countries. South Africa, Egypt and Nigeria are top importers of Chinesepharmaceutical products, with a 2017 value of over $300 million per country.

 

On the other hand, the report also underlines the challenge for Chinese companies in understanding African markets. In many of the markets government and donor-purchased medicines are a huge proportion of sales.  Linking into such channels is therefore crucial. Not only this, in four of the surveyed countries it takes under 1 week to formally register a business, but in others – countries as diverse as South Africa, Gabon and Zimbabwe – it takes over 40 days. There is added complexity if companies want to register new health products. In Ethiopia and Tanzania it takes less than 3 months, but in Kenya, Zimbabwe and Angola the process takes at least 10 months. Chinese companies are, of course, used to complex rules at home, but they and other foreign investors nevertheless need to explore the regulatory landscape carefully to determine which markets might offer the most opportunities for high-quality accessible products.

 

The Ambassador of Senegal to China Mamdou Ndiaye, speaking as the new co-chair of the Forum on China Africa Cooperation (FOCAC), for which over 40 African Heads of State visited Beijing in September 2018, welcomed the report saying “I see many Chinese enterprises in my work here in China, and I know many are not familiar with African markets. They also perceive the business environment in Africa to be weak and risky. I hope the analysis launched today – which includes my country and 20 others, will provide the information and shift perceptions to help to bring in new investors into this sector all across Africa”.

 

Thanking UNAIDS for their collaboration, the Vice President of CCCMHPIE Meng Dongping reflected “Africa is an important partner as well as a major export destination of China in pharmaceutical sector. With more than 1,600 pharmaceutical devices manufacturers, China is wildly regarded as the biggest world factory of pharmaceutical ans health commodities. Chinese companies have a willingness to strengthen cooperation with relevant parties in the international community, so as to close the gap of pharmaceuticsal supply in less developed countries.

 

At the last FOCAC summit, President Xi committed China to channelling 10 billion dollars of foreign direct investment to African countries over the next 3 years. If some of this, or more, can go towards the health sector, it will save lives. said Hannah Ryder, Development Reimagined’s CEO. “This report is the first of its kind, and it is just the first step. The approach can – and should be – applied to many other sectors. For strong, sustainable partnerships to flourish, the facts about African markets need to speak for themselves. That’s what we are sharing”.

pdf | | Download
HIV Prevention 2020 Road Map

DOCUMENTS

HIV Prevention 2020 Road Map — Accelerating HIV prevention to reduce new infections by 75%

The Road Map was prepared through a consultative process that brought together more than 40 countries and organizations, including civil society organizations, networks of people living with HIV, faith-based organizations, networks of key populations and international organizations and foundations, to chart the way forward to achieving global HIV prevention goals by 2020. Country assessments and national consultations were organized in participating countries towards reaffirming national leadership for HIV prevention, reviewing progress and discussing accelerated action for prevention. Thematic consultations and case study reviews were also conducted to develop key elements of the Road Map, most of which are also contained in a global results framework first proposed in a journal article in 2016.

pdf | | Download
Delivering as one UN The UN Joint Programme on AIDS in China 2018−2019

Table of Contents Acronyms and abbreviations 02 List of figures and tables 03 List of figures 03 List of tables 03 Preface 04 Signatures of participating United Nations organizations in the Joint Programme 06 1.Rationale for the establishment of the UN Joint Programme on AIDS 08 1.1Origins of UNAIDS 08 1.2United Nations joint teams and programmes on AIDS 09 2.Situational analysis 12 2.1China’s development context 12 2.2The role of the United Nations in China 13 2.3The HIV epidemic and response in China 14 2.4HIV and tuberculosis response in China 16 2.5Gender and other demographic characteristics of the epidemic in China 17 2.6Young people and HIV 18 3.The national AIDS strategy 21 3.1Overview of the Action Plan for the Thirteenth Five-Year Plan for Combating and Prevention of AIDS (2016–2020) 21 3.2The UN Joint Team on AIDS in China 22 3.3The UNAIDS Division of Labour 23 4.The UN Joint Programme on AIDS in China 2018–2019 26 4.1The introduction of the UN Joint Programme on AIDS in China 26 4.2The Results Framework of the UN Joint Programme on AIDS in China 28 4.2.1HIV testing and treatment and the elimination of mother-to-child transmission 28 4.2.2HIV prevention among key populations 29

pdf | | Download
UNAIDS in China: working towards ending AIDS

Table of contents ACRONYMS AND ABBREVIATIONS 1 Executive summary 2 Introduction 4 The pillars of UNAIDS’ work 4 UNAIDS Fast-Track strategy 2016–2021 5 UNAIDS in China 6 Priority area #1 8 Specific deliverables 9 Deliverable #1 9 Deliverable #2 11 Deliverable #3 13 Deliverable #4 15 Priority area #2 18 Specific deliverables 18 Deliverable #1 18 Deliverable #2 20 Deliverable #3 21 Deliverable #4 21 Deliverable #5 22 Priority Area #3 24 Specific deliverables 24 Deliverable #1 24 Deliverable #2 26 Looking forward 27 Priority area 1 27 Specific deliverables 27 Priority area 2 28 Specific deliverables 28 Priority area 3 29 Specific deliverables 29

pdf | | Download
HIV-related stigma and discrimination in China

Based on the UN joint work programme on AIDS in China (2018–2019), the Joint Team identified three areas that related to HIV stigma and discrimination as the bottleneck where the UN can provide significant added value to the national response. 1.Implementation on abolishing travel restrictions on international people living with HIV Policies and implementation guidance on the entry, stay and residence of foreigners living with HIV are harmonized and aligned for the full implementation of the 2010 Law. 2.Full employment of people living with HIV Policy review and analysis of the regulation concerning the full employment of people living with HIV in public service conducted and used for sustained advocacy. 3.Rectifying gender inequality and discrimination in health-care settings Policies and guidance implemented to end gender inequalities, gender-based violence and health care stigma and discrimination facing women living with HIV.

pdf | | Download
Facts and key messages on HIV-related stigma and discrimination in China

Background

The United Nations (UN) Joint Work Plan on AIDS in China (2018–2019) was developed based on targets set in Fast-Track countries (with explicit focus on UN support for priority country targets) that were approved by the UNAIDS Programme Coordinating Board (PCB) in June 2017. It will ensure that UN agencies provide focused support to the national AIDS response in three areas: (1) HIV testing and treatment and the elimination of mother-to-child transmission (eMTCT); (2) HIV prevention among key populations; and (3) human rights, stigma and discrimination, and gender.

pdf | | Download
UNAIDS_2017_core-epidemiology-slides

pdf | | Download
ENDING AIDS: PROGRESS TOWARDS THE 90–90–90 TARGETS

Ending AIDS: progress towards the 90–90–90 targets, gives a detailed analysis of progress and challenges towards achieving the 90–90–90 targets. The report shows that for the first time the scales have tipped: more than half of all people living with HIV (53%) now have access to HIV treatment and AIDS-related deaths have almost halved since 2005. In 2016, 19.5 million of the 36.7 million people living with HIV had access to treatment, and AIDS-related deaths have fallen from 1.9 million in 2005 to 1 million in 2016. Provided that scale-up continues, this progress puts the world on track to reach the global target of 30 million people on treatment by 2020.

pdf | | Download
HIV Care and Support

doc | | Download
The Action Plan for the Thirteen Five-Year Plan for HIV Prevention and Control

The Action Plan for the Thirteen Five-Year Plan for Combating and Prevention of AIDS

  1   2   3 
/3  PAGE  27  TOTAL
Powered by digibrother